International Journal of Gynecology & Obstetrics
Volume 88, Issue 3 , Pages 281-285, March 2005

Low-dose secnidazole in the treatment of bacterial vaginosis

  • J.T. Núñez

      Affiliations

    • Faculty of Medicine, University of Zulia, Hospital Manuel Noruega Trigo, Maracaibo, Venezuela
    • Corresponding Author InformationCorresponding author. Laboratory of Molecular Technology, National Cancer Institute, 915 Tollouse Ave, Suite 211, Frederick, Maryland, 21701, United States. Tel.: +1 301 846 6440; fax: +1 301 846 6100.
  • ,
  • G. Gómez

      Affiliations

    • Hospital Manuel Noriega Trigo, Maracaibo, Venezuela

Received 3 August 2004; received in revised form 16 November 2004; accepted 19 November 2004.

Abstract 

Objective

To determine whether bacterial vaginosis could be cured with a single 1-g oral dose of secnidazole.

Material and methods

A total of 80 women were recruited at the outpatient gynecologic clinic of Manuel Noriega Hospital, Maracaibo, Venezuela. Diagnosis and patient enrollment were based on the Amsel criteria. The participants were randomized to 2 groups. In group 1 (n=44) participants received a single 1-g oral dose and in group 2 (n=32) participants received a single 2-g oral dose of secnidazole. Clinical cure was defined as the absence of the characteristic symptoms (a bad odor and a grossly abnormal discharge) and at least 2 of the following: vaginal pH less than 4.5, no fish odor on addition of KOH, and no Gardnerella vaginalis or clue cells on wet-mount examination. Cytologic cure was defined as an absence of G. vaginalis on a Papanicolaou (Pap) smear.

Results

Clinical cure was experienced by 95.5% of the women who received the 1-g oral dose and by 97.4% of the women who received the 2-g oral dose of secnidazole. There was no significant difference between the groups in the clinical resolution of bacterial vaginosis. Following treatment, results were negative for G. vaginalis in 94.7% of the women. In group 1, 41 women (93.2%), and in group 2, 31 women (96.9%) had cytologic cure. The Pap smear revealed G. vaginalis in 3 of the women in group 1 and 1 of the women in group 2 (P=0.47). Twenty-seven women (35.5%) reported mild side effects. More women had adverse effects in group 1 (n=16) than in group 2 (n=11) but this difference was not statistically significant.

Conclusion

This clinical study showed that a single 1-g oral dose of secnidazole is effective to cure bacterial vaginosis associated with G. vaginalis.

Keywords: Secnidazole, Bacterial vaginosis, Gardnerella vaginalis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0020-7292(04)00494-1

doi:10.1016/j.ijgo.2004.11.028

International Journal of Gynecology & Obstetrics
Volume 88, Issue 3 , Pages 281-285, March 2005